1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Market Access Impact: Psoriasis (EU5)

Market Access Impact: Psoriasis (EU5)

  • April 2016
  • ID: 3866819
  • Format: PDF
  • Firstword Pharma


Table of Contents

Price and reimbursement are stopping physicians from prescribing the drugs they want.

In the psoriasis market, brands are gaining or losing market share due to, in many cases, avoidable barriers. There's a clear and huge separation in number of prescriptions between the three market leaders and the remainder of the market.

If barriers did not exist, the playing field would be significantly more level among the drugs with lower market share, and the current strongest player would lose the lead.

The report compares 8 major psoriasis treatments – Humira, Stelara, Enbrel, Remicade, Cosentyx, Inflectra, Remsima, and Otezla. You’ll get a detailed picture of what prevents doctors from prescribing your brand, who you’re losing market share to, and who you’re taking it from.

That’s information you can use to win back lost share and compete more effectively.

Not your market? Click here to see the US report

Get Answers to Key Questions about Psoriasis Drug Brands

Cosentyx (secukinumab; Novartis) – Which one barrier is most significantly effecting the prescription of this drug? Could it be overcome?
Humira (adalimumab; AbbVie) – Humira is significantly gaining against the other brands, but which factor is it that makes this the drug of choice?
Enbrel (etanercept; Pfizer) – Is Enbrel's price point benefiting its uptake or inhibiting it?
Inflectra (Infliximab, Pfizer) – Which medications are being chosen as substitutes to Inflectra and what is the primary factor causing this?
Otezla (apremilast; Celgene) – How does Otezla fall within the guidelines and what does this do to prescribing rates as compared to its competitors?
Remicade (infliximab; MSD) – Remicade has multiple preferential factors, however why is it still losing out to the market leader?
Remsima (infliximab; Mundipharma/Napp) – What factor is holding Remsima back from winning market share?
Stelara (ustekinumab; Janssen Biotech) – Which one barrier is causing the biggest loss for Stelara and could it be overcome?

Top Takeaways

Of physicians affected by barriers, many cannot prescribe the drugs they actually want: See how inability to reimburse, price, and availability on the formulary are the key inhibitors.
Fierce competition among top three drugs: the top three drugs are all making gains due to market barriers, but one is starting to outmatch the competition.
The bottom of the market are losing out most to barriers: Although a close race, a change to the condition of the barriers, or coping strategy could see one drug leave the others behind.
Losing drugs hold minimal prescription usage: The percentage of the three least prescribed drugs added together is still less than 50% than that of the leading drugs.
Stability in number of barriers experienced: Contrary to the US, all but one of the EU5 drugs finds that they have a surprisingly similar number of barriers to prescription.
Opportunity via awareness: Several drugs have the potential to grow market share due to a sizeable percentage of prescribers being unaware of their drugs.
EU and US landscapes strikingly different: The US sees drugs being inhibited by market barriers circa 50% more when compared to the EU5. See the US report to find out what other key differences there are.

Exploring Market Access Issues

Market Access Impact: psoriasis explores key issues affecting dermatology drug manufacturers. You’ll learn:Exploring Market Access Issues

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 150 Medical dermatologists —30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between January 28th – February 11th, 2016.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Custom Antibody Industry

  • $ 5600
  • March 2021
  • 272 pages

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 8 - Influencer Pool: 562 - MarketGlass™ Platform - Our influencer driven interactive research ...

  • World
  • China
  • Monoclonal Antibody
  • Polyclonal Antibody
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on